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Objectives


Examine the legal status and use of marijuana and its
derivatives in the United States.



Describe e-cigarettes & compare/contrast vaping and juuling
and FDA stand on these products.



Describe the impact that vaping and other pharmacological
therapies for tobacco smoking cessation.



Examine the adverse effects of using recreational ecigarettes, marijuana, vaping, and juuling.



Raise public awareness to prevent adolescents, teens, and
adults from smoking e-cigarettes and tobacco products.
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Background on Marijuana
 Comes

from the plant Cannabis Sativa and
Cannabis Indica
 Has been used for more than 4,000 years
 Earliest documentation of therapeutic use of
marijuana dates back to the fourth century BC in
China4

(2018). Plants Profile for Cannabis sativa (marijuana). [online] Available at: https://plants.usda.gov/core/profile?symbol=casa3 [Accessed
Plants.usda.gov.

13 Dec. 2018]
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Background on Marijuana
 Marijuana

was listed in the US Pharmacopoeia
from 1850- 1942

 In

1970, FDA listed marijuana as a scheduled I
controlled substance7

 The

Cannabis plant contains over 400 different
chemical compounds


The two most common are:
• Tetrahydrocannabinol (THC)
• Cannabidiol (CBD)
5

Background on Marijuana
Cannabis Sativa

Cannabis Indica

Tall thin stemmed with
narrow leaves

Short stemmed with
wide leaves

Longer time to mature

Faster growing and
higher yields

Medicinal derivate with
lower CBD levels

Medicinal derivate have
higher CBD levels

Medicinal derivate have
higher THC levels

Medicinal derivate have
lower THC levels
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Background on Marijuana
 Cannabinoids

is a term used to describe a
compound that agonizes the cannabinoid
receptors (CB)7






CB1
• Found in nervous system
CB2
• Located primarily in the peripheral system and recent data
supports in the nervous system
Both receptors have also been identified in the T and B
lymphocyte9

 The

receptors are G protein linked
neuromodulators that inhibits adenylate
cyclase in a dose dependent manner7
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Background on Marijuana


THC
 CBD
 A psychoactive component of
 Not a psychoactive but
marijuana7
influences the body
 Short-term effects
 Short-term effects
• Alters senses
• Tiredness
• Changes mood
• Diarrhea
• Impairs cognitive functions
• Change in appetite
 Higher doses
• Weight gain or loss
 Hallucinations, delusion,
• Decrease inflammation
and psychosis
• Reduce pain
• Reduce insomnia
 Long-term effects
• Impairment in cognitive
 Long-term effects
function
• Not well studied
8

Recreational Use
 Smoking

is the most common use of
marijuana


Joint/blunt, pipe, or a bong

 Assorted
 Mixed

with food

with a beverage as a tea

 Dabbing
9

Place in Medicine
 FDA

has not approved marijuana safe and
effective and remains a schedule I controlled
substance

 FDA

approved derivatives of marijuana:
® (Cannabidiol)
 Epidiolex


Marinol® and Syndros™ (Dronabinol)



Cesamet™ (Nabilone)
10

Epidiolex® (Cannabidiol)

The Daily Marijuana Observer. (2018). EPIDIOLEX (cannabidiol) Oral Solution – the First FDA-approved Plantderived Cannabinoid Medicine – Now Available by Prescri. [online] Available at: https://mjobserver.com/unitedstates/epidiolex-cannabidiol-oral-solution-the-first-fda-approved-plant-derived-cannabinoid-medicine-now-availableby-prescription-in-the-u-s/ [Accessed 14 Dec. 2018].
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Epidiolex® (Cannabidiol)

 Approved


for

Treatment of seizures associated with Lennox-Gastaut
syndrome or Dravet syndrome3

 Lennox-Gastaut


Onset between the age of 2 years to 18 years of age

 Dravet


Syndrome

Syndrome

Onset from infancy up to 2 years of age

12

Epidiolex® (Cannabidiol)


Dosing3
 Initial: 2.5 mg/kg twice daily
• Maintenance dose of 5 mg/kg may be increased after
tolerating for 1 week
 Max dose: 10 mg/kg twice daily



Adjustment3
 Moderate hepatic impairment (Child-Pugh class B)
• Initial: 1.25 mg/kg twice daily, may increase after
tolerating for 1 week to a dose of 2.5 mg/kg twice a day
 Maintenance dose of 2.5 mg/kg
 Max dose: 5 mg/kg twice daily
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Epidiolex® (Cannabidiol)


Severe hepatic impairment (Child-Pugh class C)3
 Initial: 0.5 mg/kg twice daily, may increase after tolerating
for 1 week to a dose of 1 mg/kg twice daily
• Maintenance dose of 1 mg/kg

Max: 2 mg/kg twice daily
Monitor
 ALT, AST, and total bilirubin
Adverse effects
 Central nervous system
 Dermatologic
 Weight loss
 GI
 Anemia
 Increase in liver enzymes
 Asthenia
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Marinol® (Dronabinol)

Akorn.com. (2018). [online] Available at:
http://www.akorn.com/documents/catalog/sell_sheets/17478-762-06.pdf
[Accessed 14 Dec. 2019].
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Marinol® (Dronabinol)
 FDA




approval to treat:6

Anorexia in patients with AIDS
Chemotherapy induced nausea and vomiting
(CINV)

16

Marinol® (Dronabinol)
 Dosing




Anorexia6
Initial: 2.5 mg twice daily 1 hour prior to meals
•May increase dose gradually based on
response to medication
Max dose: 20 mg per day
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Marinol® (Dronabinol)
 Dosing




CINV6
Initial: 5 mg/m2 1 to 3 hours prior to
chemotherapy, then 5 mg/m2 per dose every 2
to 4 hours after therapy. Total of 4 to 6 doses
per day5
•May increase dose gradually based on
response, increments of 2.5 mg/m2
Max dose: 15 mg/m2 per dose5

18

Syndros™ (Dronabinol)

Syndros.com. (2018). SYNDROS | The First & Only FDA-Approved Liquid Dronabinol.
[online] Available at: https://www.syndros.com/ [Accessed 14 Dec. 2018].
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Syndros™ (Dronabinol)
 FDA




approval to treat:10

Anorexia in AIDS patients
Chemotherapy induced nausea and vomiting
(CINV)

20

Syndros™ (Dronabinol)
 Dosing

Anorexia10
 Initial: 2.1 mg twice daily 1 hour prior to
meals
•May increase dose gradually based on
response to the medication
•Increments of 2.1 mg for the latest
meal first, then may increase to 2.1 mg
for both doses
 Max dose: 16.8 mg per day
21

Syndros™ (Dronabinol)


Dosing CINV10
2 1 to 3 hours prior to chemotherapy,
 Initial: 2.1 mg/m
then 2.1 mg/m2 per dose every 2 to 4 hours after
therapy. Total of 4 to 6 doses per day 9
• Dose rounded to nearest 0.1 mg
• May increase dose gradually based on response to the
medication
• Increments of 2.1 mg/m2 for the latest meal first, then
may increase to 2.1 mg/m2 for both doses
2 per dose9
 Max dose: 12.6 mg/m

22

Marinol® and Syndros™
(Dronabinol)
Monitor

•Heart rate
•Blood pressure
•Worsening of symptoms
Adverse

effects

•Euphoria
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Cesamet™ (Nabilone)

Cesamet.com. (2018). Cesamet (nabilone): Dosing & Administration. [online]
Available at: http://cesamet.com/hcp-dosing-and-administration.asp [Accessed 15
Dec. 2018].
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Cesamet™ (Nabilone)
 Approved


for treating1

Refractory nausea and vomiting associated with
cancer chemotherapy who have failed other
antiemetic treatments

25

Cesamet™ (Nabilone)
 Dosing1


Initial: 1 to 2 mg twice daily
• May be used 2 to 3 times a day throughout chemotherapy
regimen
• Continue up to 48 hours after last chemotherapy dose



Max dose: 6 mg per day divided into 3 doses

 Monitor


Heart rate, blood pressure, and worsening of symptoms

 Adverse




effects

Central nervous system
Xerostomia
Visual disturbances
26

Marijuana Uses by the Medical
Community
 FDA




approval

AIDS wasting
Epilepsy
Cancer and chemotherapy-induced nausea

 Non-FDA



approval

Neuropathic pain
Treatment of spasticity associated with multiple
sclerosis
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Status of Marijuana in United
States





The use of marijuana federally remains prohibited8
Recreational approval:
 Alaska, California, Colorado, District of Columbia, Maine,
Massachusetts, Michigan, Nevada, Oregon, Vermont, and
Washington
Approved for Medical use:
 Arizona, Arkansas, Connecticut, Delaware, Florida,
Hawaii, Illinois, Louisiana (can not be smoked), Maryland,
Minnesota, Missouri, Montana, New Mexico, New
Hampshire, New Jersey, New York, North Dakota, Ohio,
Oklahoma, Pennsylvania, Rhode island, Utah, WestVirginia (only for cannabis-infused products)
28

Vaping and Juuling

Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. [online] Centeronaddiction.org. Available at:
https://www.centeronaddiction.org/e-cigarettes/recreational-vaping/what-parents-should-know-about-different-vaping-devices [Accessed 15 Dec. 2018].
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Vaping
 The

act of using an electronic device to
inhale or exhale an aerosol containing
multiple chemicals






Nicotine
Propylene glycol (PG) and/or vegetable glycerin
(VG) base
Flavoring agents
Water

 Think

of vaping as an umbrella term for
any device that is an electronic nicotine
delivery system (ENDS)
30

Vaping Devices
 Multiple


device types that ranges from:

Device type/size

• Electronic cigarettes/Cig-likes
• Pen kits
• Mechanical modified nicotine deliver system (MODs)
kits
• Juul



Nicotine content
• 0-6 mg/mL
• 3-12 mg/mL
• 10-20 mg/mL



Throat hit

• Soft, medium, and hard
31

Electronic Cigarettes/Cig-likes
 First

generation of vaping devices

Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. [online]
Centeronaddiction.org. Available at: https://www.centeronaddiction.org/e-cigarettes/recreational-vaping/whatparents-should-know-about-different-vaping-devices [Accessed 15 Dec. 2018].
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Pen Kits
 Second

generation of vaping devices

Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction.
[online] Centeronaddiction.org. Available at: https://www.centeronaddiction.org/ecigarettes/recreational-vaping/what-parents-should-know-about-different-vaping-devices [Accessed 15
Dec. 2018].
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Mechanical Modified Nicotine
Deliver System (MODs) Kits
 Third

generation
 Longer battery life than previous devices
 Delivers higher amounts of nicotine as
compared to previous devices

Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. [online] Centeronaddiction.org.
Available at: https://www.centeronaddiction.org/e-cigarettes/recreational-vaping/what-parents-should-know-about-different-vaping-devices
[Accessed 15 Dec. 2018].
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Electronic Hookah
 Third

generation

Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction.
[online] Centeronaddiction.org. Available at: https://www.centeronaddiction.org/e-cigarettes/recreationalvaping/what-parents-should-know-about-different-vaping-devices [Accessed 15 Dec. 2018].
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Juul
 The

term Juuling has resulted from its growing
popularity among users
 Similar to a USB
 Marketed in various flavors
 Easy to carry and recharged

Devices, W. (2018). What Parents Should Know About the Different Vaping Devices | Center on Addiction. [online] Centeronaddiction.org. Available at: 36
https://www.centeronaddiction.org/e-cigarettes/recreational-vaping/what-parents-should-know-about-different-vaping-devices [Accessed 15 Dec. 2018].

Smoking Cessation
 Vaping

may be safer compared to smoking
cigarettes and other combustible tobacco products
 Evidence from studies supports that vaping has
less toxic elements than combustible products
 Long term effects are not known yet as this is a
new trend
 For the youth this is a problem because we are
introducing nicotine at an early age and their
brains are still developing
 Creating an addiction to these devices
 Heavy smokers may need to consider bigger
device and larger PG percentage
37

Smoking Cessation
 Vaping

is not approved among the guidelines as
an aid for quitting
 Methods to stop smoking
 Counseling
 Pharmacological
•Nicotine replacement products
 OTC
 Prescription
•Non-nicotine replacement medication
® (Bupropion SR)12
 Zyban
® (Varenicline tartrate)2
 Chantix
38

Smoking Cessation
•Nicotine Patches
Cigarette use

Week 1-6

Week 7-8

Week 9-10

≤ 10 per day

14 mg

7 mg

None

> 10 per day

21 mg

14 mg

7 mg

•Nicotine Gum
2 mg gum

4 mg gum

If 1st cigarette smoked 30 minutes or
later after waking up

If 1st cigarette smoked within 30
minutes after waking up

Smoke < 25 cigarettes a day

Smoke > 25 cigarettes a day

Week 1-6
1 gum every 1 to 2
hours

Week 7-9
1 gum every 2 to 4
hours

Week 10-12
1 gum every 4 to 8
hours
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Smoking Cessation
•Non-nicotine replacement medications


These agents serve as an aid to alleviate
nicotine withdrawal symptoms and
decreases the surges of dopamine, that is
responsible for the reward associated with
smoking

Drug

Day 1-3

After day 3

Zyban®

150 mg every morning

150 mg twice daily

Chantix®

0.5 mg daily

0.5 mg twice daily

40

Zyban® (Bupropion SR)12





Side effects:
 Xerostomia
 Insomnia
 Agitation
 Headaches
Black boxed warning:
 Risk of suicidal thinking
Contraindication12
 Patients with seizure disorder
 History of anorexia
 Using within 14 days of discontinuing MAO inhibitors
® (Linezolid)
 Patients being treated with Zyvox
41

Chantix® (Varenicline tartrate)2
 Side

effects:

Nausea
 Insomnia
 Headache


 Dose

adjustment2

CrCl<30 mL/minute initial: 0.5 mg once
daily by mouth
 Max dose: 0.5 mg twice daily
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Smoking Cessation
Smoking is the leading cause of preventable death
 480,000 deaths per year in the US associated with
smoking10
 6 million death per year world wide associated with
smoking10
 Smoking of tobacco is linked to many health problems
 Nicotine dependency
 Cancer
 Heart disease
 Respiratory issues
 Lung disease
 Infertility in women
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Quit Smoking
Limited

evidence that ENDS may be
effective as an aid to promote
smoking cessation

No

data to recommend vapes over
approved products
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Potential Harm of Vaping
Bronchiolitis

lung”

Nicotine


obliterans “Popcorn

addiction

Not considered a carcinogen, but may
lead to addiction to other tobacco
products

45

Popcorn Lung

Judith Marcin, M. (2019). Popcorn lung: Causes, symptoms, and treatment. [online] Medical News
Today. Available at: https://www.medicalnewstoday.com/articles/318260.php [Accessed 8 Jan.
2019].
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Side Effects/Risks of Vaping
Irritation

to the eyes and throat

Elevation

of heart rate and blood

pressure

E-liquid
Device

poisoning if ingested

battery explosions
47

Under 18 years of Age
 Evidence

from the 2018 National
Academies of Sciences, Engineering, and
Medicine Report (NASEM) supported that
the use of ENDS increases the risk of
children and teenagers smoking tobacco

 Moderate

evidence that ENDS use
increases frequency and intensity of
subsequent tobacco products
48

2nd Hand Smoking
Less

compared to combustible
tobacco

Vaping

indoors increases the
concentrations of particulate matter
and nicotine in indoor environment
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Public Awareness
From

the data it is apparent that
vapes may be less harmful for adults
that smoke, but this does not apply
for children and adolescent
According to the FDA many of adult
smokers started at an early age5
90% started before the age of 18
 95% started before the age of 21
 1% started after the age of 26
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Data from the 2018 National Youth
Tobacco Survey (NYTS)
 Information

provided by a collaboration of the
FDA and CDC
 The population of the survey were middle and
high school students, regarding their use of
ENDS5
 78% increase among high school students from
2017 to 2018
 48% increase among middle school students
from 2017 to 2018
 Total number of students using ENDS increased
from 1.5 million to 3.6 million
•67.8% of those students used flavored ENDS
51

FDA
 FDA

is aware of this alarming data and has
created tools to address this problem








Launched a Youth Tobacco Prevention Plan
Launched the “The Real Cost” prevention
campaign
Task force to crack down on retailers who are
selling illegal ENDS to the youth
Partnered with Federal Trade Commission
Stricter flavoring policies for all flavored ENDS
except for
• Tobacco, mint, and menthol flavor
52

Take Home Points
 Use

approved FDA methods for smoking cessation

 Long

term effects of vaping is unknown

 Adolescents

should avoid all tobacco and ENDS,
as their developing brain does not benefit from
nicotine
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Questions

True

OR

False

54

True or False
The

same therapeutic effects can be
expected from CBD oil and THC.

55

Answer

X

•True

Correct

•False
56

True or False
CBD

oil has FDA approved indication
for treating Dravet syndrome.

57

Answer

Correct

•True

X

•False
58

True or False
Vaping

does not cause addiction to
nicotine.

59

Answer

X

•True

Correct

•False
60
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